PD 188669

Drug Profile

PD 188669

Alternative Names: PD188669

Latest Information Update: 30 Aug 2007

Price : $50

At a glance

  • Originator Pfizer; Purdue Pharma
  • Class Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 16 Nov 1999 CoCensys has been acquired by Purdue Pharma
  • 16 Sep 1999 Preclinical development for Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top